ROCKVILLE, Md.--(BUSINESS WIRE)--Dec. 8, 2008--Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company
will be webcasting its presentation at the J.P. Morgan 27th
Annual Healthcare Conference scheduled for Wednesday January 14, 2009 at
8:30 am Pacific. A member of the company's senior management team will
provide a corporate overview, including a discussion of product
development programs, recent corporate activities and financial
performance.
A webcast of this presentation will be available both live and by
replay. To access either the live or archived webcast, please proceed to www.emergentbiosolutions.com,
and click on the "Investors" link the day of the presentation.
An archived replay of the webcast will be available 24 hours after the
live presentation.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a leading biopharmaceutical company
dedicated to one simple mission--to protect life. Emergent
develops, manufactures and commercializes immune-related biologics,
vaccines and biotherapeutics that assist the body's immune system to
prevent or treat infectious and other life threatening diseases.
Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is
the only vaccine approved by the U.S. Food and Drug Administration for
the prevention of anthrax infection. Emergent's clinical pipeline
includes programs focused on anthrax, botulism, typhoid, tuberculosis,
hepatitis B and chlamydia. www.emergentbiosolutions.com.
CONTACT: Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Director, Corporate Communications
301-795-1800
SchmittT@ebsi.com
Source: Emergent BioSolutions Inc.
